• Yu-Tze Ng, Joan Conry, Juliann Paolicchi, Lydia Kernitsky, Wendy Mitchell, Rebecca Drummond, Jouko Isojarvi, Deborah Lee, Randall Owen, and OV-1004 study investigators.
• University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. y-ng@ouhsc.edu
• Epilepsy Behav. 2012 Dec 1;25(4):687-94.

AbstractIn an ongoing open-label extension (OV-1004), patients with Lennox-Gastaut syndrome who had completed 1 of 2 randomized controlled trials (OV-1002 [Phase II] or OV-1012 [Phase III]) are receiving clobazam at dosages ≤2.0 mg/kg/day (≤80 mg/day). Of 306 eligible patients from OV-1002 or OV-1012, 267 entered the open-label extension. As of the interim date, July 1, 2010, 213 patients (79.8%) had remained in the trial, and 189 had received clobazam for ≥12 months, 128 for ≥18 months, and 94 for ≥24 months. Median percentage decreases in average weekly rates of drop seizures were 71.1% and 91.6% at Months 3 and 24. Mean modal and mean maximum daily dosages were 0.94 mg/kg and 1.22 mg/kg for those who had received clobazam for ≥1 year. The 4 most common adverse events were upper respiratory tract infection (18.4%), fall (14.2%), pneumonia (13.9%), and somnolence (12.7%). Clobazam's adverse event profile was consistent with its profile in controlled trials.Copyright © 2012 Elsevier Inc. All rights reserved.

23 keywords...

hide…